Prestige Consumer Healthcare (NYSE:PBH) Issues Quarterly Earnings Results

Prestige Consumer Healthcare (NYSE:PBH) posted its quarterly earnings data on Thursday. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02), FiscalAI reports. The business had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The business’s revenue for the quarter was down 2.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.22 EPS. Prestige Consumer Healthcare updated its FY 2026 guidance to 4.540-4.540 EPS.

Here are the key takeaways from Prestige Consumer Healthcare’s conference call:

• Clear Eyes supply is improving sequentially and management expects further progress in Q4 and through calendar 2026 after acquiring Pillar Five and installing a new high-speed line, which should enable internal production, SKU expansion and renewed marketing support.
• Q3 revenue of $283.4 million declined ~2.4% YoY (2.2% ex-FX) and adjusted EPS slipped to $1.14, driven primarily by Clear Eyes supply constraints and category softness in analgesics and cough & cold.
• Strong cash generation (YTD free cash flow of $208.8 million, +12.9%) underpins disciplined capital allocation: the company closed the ~$110 million Pillar Five deal and repurchased >$150 million of shares (~5% of outstanding), while maintaining net debt of ~$1 billion (leverage ~2.6x).
• Management narrowed fiscal 2026 guidance to about $1.1 billion in revenue and ~$4.54 adjusted EPS, expects Q4 adjusted gross margin ~57%, A&M just under 14% of sales and full-year G&A just over 10%, and will provide more 2027 detail on the May call.

Prestige Consumer Healthcare Stock Performance

PBH traded down $0.16 during midday trading on Friday, reaching $65.40. The company had a trading volume of 74,026 shares, compared to its average volume of 372,771. Prestige Consumer Healthcare has a 1 year low of $57.25 and a 1 year high of $90.04. The company has a market cap of $3.14 billion, a P/E ratio of 16.23, a P/E/G ratio of 2.10 and a beta of 0.43. The business has a 50-day moving average of $63.05 and a two-hundred day moving average of $64.13. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the sale, the vice president owned 42,329 shares of the company’s stock, valued at $2,539,740. The trade was a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Danske Bank A S bought a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter worth approximately $37,000. Brown Brothers Harriman & Co. purchased a new position in Prestige Consumer Healthcare in the 3rd quarter worth about $44,000. Geneos Wealth Management Inc. lifted its holdings in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after buying an additional 269 shares in the last quarter. CIBC Private Wealth Group LLC boosted its position in Prestige Consumer Healthcare by 142.8% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company’s stock valued at $69,000 after buying an additional 647 shares during the period. Finally, State of Wyoming bought a new position in Prestige Consumer Healthcare in the 2nd quarter worth about $97,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Key Headlines Impacting Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Management says Clear Eyes supply is recovering, reducing a prior headwind to sales; progress on SKU availability could support revenue in coming quarters. Prestige Consumer Healthcare narrows fiscal 2026 revenue outlook to $1.1B while advancing Clear Eyes supply recovery
• Positive Sentiment: Company reiterated solid profitability metrics (net margin ~18% and ROE ~12.4% reported for the quarter), indicating resilient cash generation and operating leverage. Q3 and year-to-date results press release
• Neutral Sentiment: The company narrowed FY‑2026 guidance to EPS of 4.54 and revenue of ~$1.1B, which increases forecast clarity but largely matches street revenue expectations while missing EPS consensus by a penny. Q3 revenue tops estimates, narrows guidance
• Neutral Sentiment: Company provided an earnings presentation and full call transcript for details on category trends and cost actions — useful for investors digging into channel inventory, promotional cadence and timing of Clear Eyes recovery. Q3 earnings call transcript
• Negative Sentiment: Reported EPS of $1.14 missed consensus (~$1.16) and declined from $1.22 year‑ago, a straight earnings miss that pressured sentiment. Q3 Earnings Lag Estimates
• Negative Sentiment: Quarterly revenue was roughly $283.4M (down ~2.4% YoY) and reports vary on whether the quarter beat/lagged consensus — the topline softness and channel dynamics likely weighed on the stock. Q3 results summary and slide deck

Wall Street Analyst Weigh In

PBH has been the subject of a number of research reports. Jefferies Financial Group dropped their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Oppenheimer cut their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Canaccord Genuity Group cut their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Finally, Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $84.50.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).